Published in Pharmacogenetics on May 01, 2004
The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets (2007) 1.86
5-HT3 receptors. Curr Pharm Des (2006) 1.49
Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag (2009) 1.10
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. J Cancer Res Clin Oncol (2008) 0.89
New directions in supportive care. Support Care Cancer (2004) 0.88
Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm (2011) 0.85
Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr Oncol Rep (2013) 0.80
Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study. BMC Pregnancy Childbirth (2013) 0.80
Does granisetron eliminate the gag reflex? A crossover, double-blind, placebo-controlled pilot study. Anesth Prog (2009) 0.78
Association between serotonin transport polymorphisms and postdischarge nausea and vomiting in women following breast cancer surgery. Oncol Nurs Forum (2014) 0.77
Association of 5-HT3B Receptor Gene Polymorphisms with the Efficacy of Ondansetron for Postoperative Nausea and Vomiting. Yonsei Med J (2015) 0.77
Sequence variants of the HTR3A gene contribute to the genetic prediction of postoperative nausea in Taiwan. J Hum Genet (2014) 0.75
Influence of Polymorphisms in the HTR3A and HTR3B Genes on Experimental Pain and the Effect of the 5-HT3 Antagonist Granisetron. PLoS One (2016) 0.75
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 2.97
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol (2009) 2.13
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09
Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics (2006) 2.07
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation (2005) 1.87
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics (2002) 1.85
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol (2007) 1.84
Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther (2005) 1.83
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol (2002) 1.75
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol (2002) 1.73
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics (2003) 1.63
Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst (2012) 1.62
Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol (2004) 1.58
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther (2002) 1.58
Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int (2005) 1.58
Endothelin-1 gene variant Lys198Asn and plasma endothelin level in obstructive sleep apnea. Cardiology (2008) 1.47
Genome-wide single-nucleotide polymorphism arrays demonstrate high fidelity of multiple displacement-based whole-genome amplification. Electrophoresis (2005) 1.45
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Primary tumor excision in stage IV breast cancer at diagnosis without influence on survival: a retrospective analysis and review of the literature. Onkologie (2011) 1.44
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther (2004) 1.43
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther (2002) 1.42
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos (2002) 1.40
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol (2013) 1.39
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet (2005) 1.36
Pharmacogenetics-based therapeutic recommendations--ready for clinical practice? Nat Rev Drug Discov (2005) 1.35
Biomarkers of depression in cancer patients. Cancer (2006) 1.32
The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs (2008) 1.31
Angiogenesis in multiple myeloma. Eur J Cancer (2006) 1.31
Myeloma bone disease and proteasome inhibition therapies. Blood (2007) 1.29
CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis (2003) 1.28
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol (2006) 1.27
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol (2008) 1.26
Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol (2004) 1.23
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood (2006) 1.22
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol (2006) 1.21
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol (2003) 1.20
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol (2013) 1.19
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica (2006) 1.16
The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem (2004) 1.16
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem (2005) 1.14
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma (2010) 1.14
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res (2003) 1.14
Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos (2008) 1.14
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol (2008) 1.13
Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics (2008) 1.12
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res (2012) 1.11
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol (2007) 1.11
Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol (2013) 1.11
Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol (2008) 1.11
Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2003) 1.11
Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies. Pharmacogenomics (2010) 1.10
Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol (2008) 1.10
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol (2003) 1.09
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol (2003) 1.09
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther (2006) 1.07
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun (2005) 1.07
Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma. Br J Clin Pharmacol (2004) 1.07
Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. Eur J Pharmacol (2008) 1.07
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer (2007) 1.07
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer (2008) 1.07
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol (2009) 1.05
Proteasome: an emerging target for cancer therapy. Anticancer Drugs (2005) 1.04
Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol (2003) 1.04
AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit (2006) 1.04
An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients. Eur J Cancer (2010) 1.03
Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain (2009) 1.03
Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant (2003) 1.03
Identification of clinically relevant yeasts by PCR/RFLP. J Microbiol Methods (2004) 1.02
Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics (2008) 1.02
Gene expression profile of adult human bone marrow-derived mesenchymal stem cells stimulated by the chemokine CXCL7. Int J Biochem Cell Biol (2008) 1.01